|
Originally published In Press as doi:10.1074/jbc.M206126200 on July 18, 2002
J. Biol. Chem., Vol. 277, Issue 38, 35393-35401, September 20, 2002
Role of Amino Acid Residues in Transmembrane Segments IS6 and
IIS6 of the Na+ Channel Subunit in
Voltage-dependent Gating and Drug Block*
Vladimir
Yarov-Yarovoy,
Jancy C.
McPhee,
Diane
Idsvoog,
Caroline
Pate,
Todd
Scheuer, and
William A.
Catterall
From the Department of Pharmacology, University of Washington,
Seattle, Washington 98195-7280
Received for publication, June 20, 2002, and in revised form, July 16, 2002
 |
ABSTRACT |
Alanine-scanning mutagenesis of transmembrane
segments IS6 and IIS6 of the rat brain Nav1.2 channel
subunit identified mutations N418A in IS6 and L975A in IIS6 as
causing strong positive shifts in the voltage dependence of activation.
In contrast, mutations V424A in IS6 and L983A in IIS6 caused strong
negative shifts. Most IS6 mutations opposed inactivation from closed
states, but most IIS6 mutations favored such inactivation. Mutations
L421C and L983A near the intracellular ends of IS6 and IIS6,
respectively, exhibited significant sustained Na+ currents
at the end of 30-ms depolarizations, indicating a role for these
residues in Na+ channel fast inactivation. These residues,
in combination with residues at the intracellular end of IVS6, are well
situated to form an inactivation gate receptor. Mutation I409A in IS6
reduced the affinity of the local anesthetic etidocaine for the
inactivated state by 6-fold, and mutations I409A and N418A reduced
use-dependent block by etidocaine. No IS6 or IIS6 mutations
studied affected inactivated-state affinity or
use-dependent block by the neuroprotective drug
sipatrigine (compound 619C89). These results suggest that the
local anesthetic receptor site is formed primarily by residues in
segments IIIS6 and IVS6 with the contribution of a single amino acid in
segment IS6.
 |
INTRODUCTION |
Voltage-gated Na+ channels are integral membrane
proteins that are responsible for the initiation and propagation of
action potentials in nerve and muscle cells (1-5). The rat brain
Na+ channel as isolated biochemically consists of (260 kDa), 1 (36 kDa), and 2 (33 kDa) subunits
(2). The subunit is composed of four homologous domains (I-IV),
each with six transmembrane segments (S1-S6) and an additional
membrane-reentrant pore loop (P-loop) between segments S5 and S6 (2, 4,
5). Analogous to the structural topology of pore-forming M2 segments of
the K+ channel from Streptomyces lividans (KcsA)
(6), the S6 segments from each domain of the Na+ channel
are thought to be arranged in a square array surrounding the inner
pore, whereas P-loops from each domain line the outer pore and form the
ion selectivity filter (2, 4, 5).
Voltage-gated Na+ channel activation is thought to result
from a voltage-driven outward movement of gating charges, which
initiates a conformational change in the protein that opens the channel (7, 8). Analysis of the primary structure of the Na+
channel subunit led to the prediction that S4 transmembrane segments, which contain repeated motifs of positively charged arginine
and lysine residues every three amino acids, might serve as the voltage
sensor (9, 10). Depolarization of the membrane was proposed to cause
the S4 segments to move outward, inducing a conformational change in
the pore of the channel resulting in activation. Site-directed
mutagenesis studies have demonstrated that the positively charged
residues in all four S4 segments contribute to the
voltage-dependent activation of the Na+ channel
(11, 12). The proposed outward movement of the S4 segments has been
directly detected using mutagenesis, covalent modification, and
fluorescent imaging experiments (13-15). Thus, the S4 segments play a
critical role in voltage-dependent activation. Na+ channel fast inactivation occurs within a few
milliseconds of channel opening and is mediated by the intracellular
loop connecting domains III and IV (16, 17). Mutagenesis studies of
this loop revealed three hydrophobic residues (isoleucine,
phenylalanine, and methionine (IFM motif)) that are critical for fast
inactivation (18). Scanning mutagenesis experiments have identified
multiple amino acid residues that may form the inactivation gate
receptor within and near the intracellular mouth of the pore, including a cluster of three hydrophobic residues at the intracellular end of
segment S6 in domain IV (segment IVS6) (19, 20) and residues in
intracellular loops S4-S5 in domain III (21) and S4-S5 in domain IV
(22-25). The voltage dependence of Na+ channel
inactivation derives largely from coupling to the activation process
(8). Mutagenesis studies have provided strong evidence that outward
movement of the S4 segments in domains III and IV initiates a
conformational change that leads to fast inactivation of the
Na+ channel by closure of the intracellular inactivation
gate (14, 26-28).
Alanine-scanning mutagenesis was previously used to investigate the
role of amino acid residues in the S6 transmembrane segments of domains
III and IV of the Na+ channel in
voltage-dependent gating and block by clinically important drugs (19, 20, 29-31). A number of mutations in segments IIIS6 and
IVS6 of the rat brain type IIA Na+ channel subunit,
designated the Nav1.2 channel according to the nomenclature
of Goldin et al. (32), produced strong shifts in the voltage
dependence of steady-state activation and inactivation, suggesting that
the native residues at those positions might play a particularly
important role in the voltage-dependent gating of
Na+ channels (20, 30). An -helical pattern of the shifts
in the voltage dependence of activation and inactivation produced by
alanine mutations in the inner two-thirds of segment IIIS6 suggested
rotational movement of segment IIIS6 during channel gating (30).
Specific amino acid residues in segments IIIS6 and IVS6 were identified
that form the receptor sites for Na+ channel pore-blocking
drugs such as local anesthetics and antiarrhythmic and anticonvulsant
drugs (29-31). Mutations F1764A and Y1771A in segment IVS6 of the rat
brain Nav1.2 channel reduced the affinity of inactivated
Na+ channels for the local anesthetic etidocaine by 130- and 35-fold, respectively (29). Mutation of Phe1764 and
Tyr1771 in the Nav1.2 channel and their
homologs in other Na+ channels also substantially reduced
block of inactivated Na+ channels by other local
anesthetics and antiarrhythmic and anticonvulsant drugs (29, 33-39).
Less dramatic disruptions in inactivated-state block by etidocaine were
observed with mutations L1465A, N1466A, and I1469A in segment IIIS6 of
the rat brain Nav1.2 channel, resulting in 6-, 8-, and
7-fold reduction in affinity, respectively (30). Mutations L1465A and
I1469A also reduced the inactivated-state affinity for the
anticonvulsant lamotrigine and its congeners (30). Lysine mutations of
rat skeletal muscle Nav1.4 channel Ser1276 and Leu1280 (homologous to
Leu1465 in the rat brain Nav1.2 channel) in
segment IIIS6 reduced the inactivated-state affinity for the local
anesthetic bupivacaine by 7-17-fold (40). Lysine mutations of rat
skeletal muscle Nav1.4 channel Asn434 and
Leu437 in segment IS6 reduced the inactivated-state
affinity for etidocaine by 7- and 3-fold, respectively (41).
In this work, we have undertaken a systematic analysis of the role of
segments IS6 and IIS6 of the rat brain Nav1.2 channel in
channel gating and in block by local anesthetics and anticonvulsant drugs using alanine-scanning site-directed mutagenesis. Our results identify individual residues in segments IS6 and IIS6 that are important for Na+ channel activation and inactivation
gating and also define novel determinants of the receptor site for the
local anesthetics.
 |
EXPERIMENTAL PROCEDURES |
Mutagenesis of Rat Brain Nav1.2
Channels--
Mutations were prepared by a two-step PCR protocol using
two mutagenic primers and two restriction site primers. The mutagenic fragment and the plasmid pCDM8-Nav1.2 were digested with
BstEII and BlpI restriction endonucleases. The
mutagenic fragment was then subcloned into the pCDM8-Nav1.2
plasmid via those restriction sites. The mutations were confirmed by
restriction mapping and DNA sequence analysis.
Na+ Channel Expression in Xenopus
Oocytes--
Plasmids encoding wild-type and mutant Na+
channel subunits and wild-type 1 subunits were
linearized, and RNA was transcribed as described previously (20).
Xenopus laevis oocytes were harvested, maintained, and injected with RNA by standard methods as described previously (20) with the following modifications. Oocytes were separated and defolliculated by shaking gently for 2 h in 1.5 mg/ml collagenase in 82 mM NaCl, 20 mM
MgCl2, 2 mM KCl, and 5 mM HEPES (pH
7.5). After an overnight incubation at 18 °C in 96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES (pH 7.4)
supplemented with 5% horse serum and 50 mg/ml gentamycin, healthy
stage V and VI oocytes were pressure-injected with 55 nl of a 10:1
mixture of wild-type 1 and wild-type or mutant rat brain
Nav1.2 channel subunit mRNA, with the subunit
concentration ranging from 10 to 100 ng/µl of injected solution.
Two-microelectrode Voltage-clamp Recordings from
Oocytes--
Na+ channel recordings were obtained from
injected oocytes using a Dagan CA-1 voltage clamp as described (20).
The bath was continuously perfused with Ringer's solution containing
115 mM NaCl, 2.5 mM KCl, 1.8 mM
CaCl2, and 10 mM HEPES (pH 7.2), adjusted with
NaOH. Recording electrodes contained 3 M KCl and had
resistances of <0.5 megaohms. The stock solution of etidocaine (Astra)
was dissolved in dimethyl sulfoxide, and sipatrigine (compound 619C89; a generous gift of Dr. Jeff Clare, GlaxoSmithKline) was prepared in 25 mM HCl. Drug stocks were then diluted to the desired
concentration in Ringer's solution.
Multiple Sequence Alignment of the S6 Transmembrane Segments of
the Rat Brain Nav1.2 Channel--
Multiple sequence
alignment of all four S6 transmembrane segments of the rat brain
Nav1.2 channel was performed using ClustalX (42). The
BOXSHADE program (Version 3.21, written by K. Hofmann and M. Baron) was
used for shading the multiple sequence alignment with the fraction of
sequences that must agree for shading set to 0.8. This threshold is the
fraction of residues that must be identical (black) or similar
(gray) for shading to occur.
Three-dimensional Modeling of the S6 Transmembrane Segments of
the Rat Brain Nav1.2 Channel--
The KcsA channel
structure (6) was used for homology modeling of the S6 transmembrane
segments of the rat brain Nav1.2 channel using Molecular
Operating Environment software (Chemical Computing Group). The proposed
pore-facing residues of the S6 segments of the Nav1.2
channel (see "Results") were aligned with the pore-facing residues
of segment M2 of KcsA. The S6 segments were arranged in a clockwise
pattern (43, 44).
 |
RESULTS |
Effect of Mutations in Segments IS6 and IIS6 on
Voltage-dependent Activation of Na+
Channels--
To investigate the functional role of amino acid
residues in transmembrane segments IS6 and IIS6 of the rat brain
Nav1.2 channel in activation, inactivation, and binding of
pore-blocking drugs, we substituted alanine sequentially for the native
amino acids at each position from Phe405 to
Val424 in segment IS6 and from Phe963 to
Leu983 in segment IIS6. Alanine substitution changes the
size and chemical properties of the residues, but has little or no
effect on protein secondary structure (45, 46). We coexpressed the
wild-type (WT)1 or mutant
Nav1.2 channel subunit and the wild-type
1 subunit in Xenopus oocytes and used
two-microelectrode voltage-clamp recording to measure Na+
currents (Fig. 1, inset).
Twenty-nine mutant Nav1.2 channels conducted sufficient
Na+ currents for analysis, and 27 of these had rapid
kinetics of activation and rapid and complete inactivation like the WT
channel (Fig. 1, inset; see Fig. 3 below for analysis of two
mutants with altered kinetics of inactivation). Seven alanine mutants
in segment IS6 (V408A, S413A, F414A, I417A, I420A, L421A, and V423A)
and five alanine mutants in segment IIS6 (V968A, L977A, L979A, L981A, and L982A) did not express sufficient Na+ currents for
analysis (generally <0.1 µA). Of the seven residues in segment IS6
that did not express when substituted with alanine, only L421C
expressed sufficient Na+ current for analysis when
mutated to cysteine.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of point mutations in segments IS6 and
IIS6 on Na+ channel activation. Conductance-voltage
curves for wild-type ( ), N418A ( ), V424A ( ), L975A ( ), and
L983A ( ) channels are shown. Peak current versus voltage
relationships were measured using 30-ms test pulses to potentials from
50 to +70 mV from a holding potential of 90 mV. Conductance was
determined as IP/(VR V), where IP is a peak inward current,
VR is the reversal potential, and V is
the test pulse voltage. Normalized conductance was fit with a single
Boltzmann relationship of the form G(V) = 1/(1 + exp((V V0.5)/k)), where
V0.5 is the half-maximal activation voltage and
k is a slope factor. Mean V0.5 and
k values were determined for each mutant. The curves shown
are plots of the Boltzmann relationship calculated using these mean
values. Inset, current traces obtained during
depolarizations from the holding potential to 0 mV in oocytes
expressing wild-type and V424A channels.
|
|
Only four mutations in segments IS6 and IIS6 caused strong positive or
negative shifts in the voltage dependence of activation compared with
the wild-type channel. Mutations N418A and L975A shifted the voltage
for half-maximal activation positively by +21 and +17 mV, respectively
(Fig. 1). Mutations V424A and L983A shifted the voltage for
half-maximal activation negatively by 11 and 10 mV, respectively
(Fig. 1). The slope factor of the voltage dependence of the activation
was significantly less steep for N418A (k = 8.0 ± 0.2 mV) and L421C (k = 7.6 ± 0.4 mV) compared with the wild-type channel (k = 5.8 ± 0.2 mV).
Effects of Mutations in Segments IS6 and IIS6 on Steady-state
Inactivation of Na+ Channels--
Mutations throughout
segments IS6 and IIS6 caused significant shifts in the voltage
dependence of inactivation, which was determined using a test pulse
applied after a 100-ms voltage step to the indicated membrane
potentials. For example, mutations L416A, L421C, and L983A shifted the
voltage for half-maximal inactivation positively by +8, +5, and +3 mV,
respectively (Fig. 2). The steady-state inactivation curve for L421C and L983A approached nonzero asymptotes with strong depolarizations (Fig. 2). This residual, non-inactivating component of the Na+ current was 6% for L421C and 7% for
L983A. Significant positive shifts were also caused by mutations F405A,
L411A, Y415A, N418A, and V966A (see Fig. 8, Inactivation
Shift). Mutations V424A, M967A, and V974A shifted the voltage for
half-maximal inactivation negatively by 7, 11, and 11 mV,
respectively (Fig. 2). Significant negative shifts were also caused by
mutations I969A, L972A, and N976A (see Fig. 8, Inactivation
Shift). Most of the mutations giving significant positive shifts
are in segment IS6 (see Fig. 8, red), indicating that native
residues at those positions favor closed-state inactivation. In
contrast, most of the mutations giving significant negative shifts are
in segment IIS6 (see Fig. 8, yellow), so native residues at
those positions oppose closed-state inactivation.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of point mutations in segments IS6
and IIS6 on Na+ channel steady-state inactivation.
Steady-state inactivation curves for wild-type ( ), L416A ( ),
L421C ( ), V424A ( ), M967A ( ), V974A ( ), and L983A ( )
channels are shown. Inactivation curves were measured using 100-ms
prepulses to the indicated potentials, followed by a test pulse to 0 mV. Peak test pulse current was plotted as a function of prepulse
potential, normalized, and fit with a Boltzmann function:
I = 1/(1 + exp((V V0.5)/k)), where
V0.5 is the membrane potential at the
half-maximal current and k is a slope factor. Mean
V0.5 and k values were determined for
each mutant. The curves shown are plots of the Boltzmann function using
these mean values.
|
|
Point Mutations in Segments IS6 and IIS6 Affect Open-state Fast
Inactivation--
Two mutations in segments IS6 and IIS6 caused
incomplete inactivation from the open state, resulting in sustained
current at the end of a 30-ms depolarization (Fig.
3A). Mutations L421C in
segment IS6 and L983A in segment IIS6 exhibited non-inactivating currents, which were ~10 and 16% of the peak current, respectively (Fig. 3B). These sustained Na+ currents were
also observed at the end of 100-ms prepulses in measurements of
steady-state inactivation (Fig. 2). Other segment IS6 and IIS6
mutations studied did not affect the inactivation from the open state
significantly.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of point mutations in segments IS6 and
IIS6 on Na+ channel inactivation during
depolarizations. A, representative current traces for
wild-type, L421C, and L983A channels. Currents were evoked by 30-ms
pulses to +5 mV for the wild-type and L421C channels and to 0 mV for
the L983A channel from a holding potential of 90 mV. Normalized
currents are shown. B, fraction of current that failed to
inactivate for wild-type, L421C, and L983A channels. Currents were
elicited as described for A. The fraction of
non-inactivating current was determined as the current 30 ms after the
beginning of the pulse divided by the peak inward current. Error
bars indicate S.E. The asterisks indicate significant
differences from the wild-type channels as determined by a t
test (p < 0.01).
|
|
Significant sustained currents produced by mutations L421C and L983A
suggest that these two residues might interact either directly or
allosterically with the inactivation gate of the Na+
channel, which is formed by the intracellular loop between domains III
and IV. Leu421 is positioned near the cytoplasmic end of
segment IS6, and Leu983 is positioned at the cytoplasmic
end of segment IIS6. Three alanine mutations of residues in the
cytoplasmic end of segment IVS6 also caused incomplete inactivation
(19, 20). No alanine substitutions disrupted inactivation from the open
state in segment IIIS6 (30). Taken together, these data suggest an
important role of several hydrophobic residues at the cytoplasmic ends
of segments IS6, IIS6, and IVS6 in Na+ channel fast
inactivation gating.
Effects of Mutations in Segments IS6 and IIS6 on the Affinity of
Inactivated Na+ Channels for Local Anesthetics and
Anticonvulsant Drugs--
Voltage-gated Na+ channel
pore-blocking drugs, including local anesthetics and antiarrhythmic and
anticonvulsant drugs, act by inhibiting ionic currents through the
channel. The potency of these drugs stems from their ability to
selectively block open and inactivated Na+ channels during
abnormal membrane depolarizations and rapid bursts of action potentials
that characterize neuronal and cardiac pathologies (47-49). This
preferential drug binding to the open and inactivated states rather
than the resting channel states can be explained by an allosteric model
in which a modulated drug receptor is in a low affinity conformation
when the channel is in the resting state and transforms to a high
affinity conformation when the channel is opened or inactivated by
depolarization (47, 48).
The local anesthetic etidocaine, the anticonvulsant lamotrigine, and
its tricyclic congener sipatrigine, formerly termed compound 619C89 (50-52) were previously used to identify specific amino acid residues involved in binding of pore-blocking drugs in
transmembrane segments IIIS6 and IVS6 (29-31). In this study, we used
etidocaine and sipatrigine for screening of mutants in segments IS6 and
IIS6. Etidocaine is used for epidermal, local, and retrobulbar
anesthesia. Sipatrigine is being evaluated in clinical trials for the
prevention of neuronal toxicity following stroke (52-55). Both of
these compounds have higher affinity for inactivated than for resting
Na+ channels, like other local anesthetics or
anticonvulsant drugs, and also are effective
frequency-dependent blockers (29-31, 50). Block of
inactivated Na+ channels was determined during a test pulse
to 0 mV following a 15-s depolarization to a holding potential at which
70-80% of the Na+ current was inactivated (Fig.
4A, inset,
trace c). At this depolarized holding potential ( 50 mV for
the wild-type Na+ channel), addition of 5 µM
etidocaine reduced the Na+ current by 70% (Fig.
4A, inset, trace d). Only 5% of the
Na+ current was blocked by the same concentration of
etidocaine when the holding potential was 120 mV (Fig. 4A,
inset, traces a and b). The apparent
dissociation constants for the inactivated state (KI) for the wild-type and mutant Na+
channels were determined from the degree of block at the depolarized potential according to Kuo and Bean (56). Wild-type Na+
channels were inhibited by etidocaine with a KI of
~2 µM under our experimental conditions (30). Mutation
I409A caused the largest decrease in affinity for etidocaine of all
studied mutations (6-fold increase in KI;
p < 0.01) (Fig. 4A). F410A and V424A in
segment IS6 also increased the KI of etidocaine, but
only by ~2-fold (p 0.01) (Fig. 4A). Of
all the segment IIS6 mutations studied, only F978A and L983A increased the KI of etidocaine significantly, and their
effects were <2-fold (p 0.02) (Fig. 4B).
Interestingly, none of the mutations studied in segments IS6 and IIS6
had significant effects on the affinity of inactivated channels for
sipatrigine (data not shown). Likewise, mutations I409A, F410A, N418A,
V424A, F978A, and L983A did not significantly affect the affinity of
inactivated channels for the anticonvulsant lamotrigine.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Affinity of inactivated wild-type and segment
IS6 and IIS6 mutant Na+ channels for etidocaine.
A: inset, representative current traces for the
wild-type channel in the absence (traces a and c)
and presence (traces b and d) of 5 µM etidocaine. Traces a and b were
measured during a test pulse to 0 mV following a 15-s conditioning
pulse to 120 mV. Traces c and d were measured
during a test pulse to 0 mV following a 15-s conditioning pulse to 50
mV. A and B: apparent dissociation constants for
block of inactivated segment IS6 and IIS6 mutant Na+
channels by etidocaine, respectively. For mutant Na+
channels, the depolarized holding potential was varied so that 70-80%
of the channels were inactivated after the 15-s conditioning prepulse.
For N418A, activation was shifted positively by ~21 mV, and the slope
factor of the activation process was less steep, so a test pulse of +40
mV was used. For L975A, activation was shifted positively by ~17 mV,
so the test pulse was +20 mV. The dissociation constant for the
inactivated state (KI) for each mutant was
calculated according to Kuo and Bean (56) as KI = (1 h)(Emax/E 1)[D], where h is the fraction of
inactivated channels, Emax is the maximal block
that is assumed to be the complete block of the current, and
E is the amount of block at the drug concentration
([D]). Error bars indicate S.E. The
asterisk indicates a significant difference from the
wild-type channel as determined by a t test
(p < 0.01).
|
|
Effects of Mutations in Segments IS6 and IIS6 on Resting-state
Block by Etidocaine--
Block of Na+ channels at a
holding potential of 90 mV mainly reflects drug binding to the
resting state of the channel (47, 48, 57). To determine whether segment
IS6 and IIS6 mutants affected block of resting Na+
channels, we applied 15-ms test pulses from a holding potential of 90
mV in the absence and presence of 100 µM etidocaine. No segment IS6 and IIS6 mutations caused significant decreases in resting
affinity for etidocaine (data not shown). Mutations Y415A, M967A,
N971A, and V974A significantly increased resting block by etidocaine at
a holding potential of 90 mV by 3-, 2-, 6-, and 2-fold, respectively
(p < 0.01) (Fig. 5).
Because of the preferential state-dependent drug binding to
inactivated Na+ channels, it was possible that the apparent
increases in affinity were secondary to changes in the voltage
dependence of inactivation rather than a reflection of actual changes
in resting channel affinity. Mutation Y415A shifted the voltage
dependence of inactivation positively by +4 mV, so it opposed
inactivation rather than enhancing it; and mutation N971A did not have
any effect on the inactivation (see Fig. 8). However, mutations M967A
and V974A shifted the voltage dependence of inactivation negatively by
11 mV each (Fig. 2). These negative shifts increased the proportion
of inactivated channels at 90 mV, which could have caused the
apparent increase in resting-state block for these mutants. Therefore,
we examined block at more negative potentials. Consistent with this
hypothesis, the affinity of WT channels for etidocaine decreased at
more negative holding potentials (Vh),
and a greater decrease was observed for V974A and M967A channels. The
differences between the WT and mutant channels became insignificant at
the most negative potentials (p > 0.05). In contrast,
the resting affinities of Y415A and N971A decreased little with further
hyperpolarization from 90 mV, and resting affinities for etidocaine
were >3-fold greater than that of the WT channel at 120 mV
(p < 0.01) (Fig. 5), indicating that these mutations
increased the affinity of resting Na+ channels for
etidocaine.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Affinity for block of resting Na+
channels by etidocaine. The voltage dependence of the equilibrium
dissociation constant (Kr) for block of resting
wild-type and mutant Na+ channels by etidocaine is shown.
15-ms test pulses to 0 mV were applied after stepping to the indicated
holding potentials (Vh) for 60 s.
Kr was calculated according to a single-site binding
isotherm: Kr = [D]((1/E) 1), where E
represents the fraction of current remaining at the drug concentration
([D]). , WT channel; , Y415A; , M967A; ,
N971A; , M974A.
|
|
Effects of Mutations in Segments IS6 and IIS6 on
Frequency-dependent Block by Etidocaine and
Sipatrigine--
Frequency-dependent block of
Na+ channels by pore-blocking drugs during rapid trains of
depolarizing pulses results from preferential binding of the drug to
open and inactivated channels and from slower recovery of drug-bound
channels between pulses (47, 48). Etidocaine and sipatrigine are strong
frequency-dependent blockers (29-31, 50). To determine
whether segment IS6 and IIS6 mutants alter
frequency-dependent block by etidocaine, we applied 2-Hz trains of 20-ms pulses to 0 mV from a holding potential of 90 mV. For
N418A, activation was shifted positively by +21 mV, and channels
activated less steeply with voltage. Therefore, a test pulse of +40 mV
was used to compensate for these voltage shifts. Mutation I409A
significantly reduced frequency-dependent block by
etidocaine, and frequency-dependent block was almost
completely abolished by mutation N418A (Fig.
6). No other segment IS6 mutations affected frequency-dependent block by etidocaine, and it was
not significantly affected by any segment IIS6 mutation. No segment IS6 or IIS6 mutation had a significant effect on
frequency-dependent block by sipatrigine (data not
shown).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Frequency-dependent block of
wild-type and mutant Na+ channels by etidocaine.
Frequency-dependent block of wild-type and mutant
Na+ channels by 100 µM etidocaine is shown.
The cells were held at 90 mV and stimulated by 20-ms test pulses to 0 mV in 2-Hz pulse trains. For N418A, activation was shifted positively
by ~21 mV, and the slope factor of the activation process was less
steep. Therefore, a test pulse of +40 mV was used. The peak current
amplitude in response to each pulse in the presence of the drug was
measured, normalized with respect to peak current for the corresponding
pulse before drug application, and plotted versus the pulse
number.
|
|
Effect of Mutations I409A and N418A on Recovery of Na+
Channels from Inactivated-state Etidocaine Block--
We studied
recovery of etidocaine-blocked inactivated Na+ channels to
the resting state for mutations I409A and N418A, which significantly
affected voltage- and frequency-dependent block of
Na+ channels by etidocaine. We measured the rate of
recovery by applying a 500-ms conditioning prepulse to 0 mV (to +40 mV
for N418A; see above) to produce drug block of inactivated channels,
followed by a recovery interval of variable duration and a test pulse
to 0 mV (to +40 mV for N418A). Recovery under control conditions followed a double-exponential time course with fast
( fast) and slow ( slow) time constants
(Fig. 7, A-C, closed
circles). The wild-type channels recovered with
fast = 5.2 ± 0.8 ms and
slow = 134 ± 12 ms (Fig. 7A). I409A
recovered with fast = 4.5 ± 0.2 ms and
slow = 143 ± 12 ms (Fig. 7B), which
were similar to the wild-type kinetics. In contrast, N418A recovered
with fast = 1.2 ± 0.2 ms or ~4-fold faster than
the wild-type channels and with slow = 337 ± 28 ms
or at least 2.5-fold slower than the wild-type channels (Fig.
7C). This time constant is a minimum estimate because only
~80% of the N418A current had recovered after 4 s (Fig.
7C), whereas 100% of the WT current had recovered after 400 ms (Fig. 7A). These data indicate that mutation N418A is
characterized by a slow inactivated state with far slower recovery kinetics than the WT channel. Alanine mutation of the homologous residue in the rat skeletal muscle Nav1.4 channel,
Asn434, also enhances slow inactivation (58). Thus, the
native asparagine in segment IS6 is critical for setting slow
inactivation properties of Na+ channels.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 7.
Recovery of the wild-type and mutant
Na+ channels from block of inactivated channels by
etidocaine. A-C, representative time courses of
Na+ channel recovery from inactivation under control
conditions ( ) and in the presence of 100 µM etidocaine
( ) for wild-type (A), I409A (B), and N418A
(C) channels. Recovery was measured using a 500-ms
conditioning pulse to 0 mV (to +40 mV for N418A), followed by a
recovery interval of the indicated duration (1.5-4000 ms) at 90 mV,
followed by a test pulse to 0 mV (to +40 mV for N418A). The peak test
pulse current was divided by the peak conditioning pulse current and
plotted against the recovery time interval. The curves are
least-squares fits of a two-exponential function to the data.
|
|
In the presence of 100 µM etidocaine, the fast time
constant reflects recovery from inactivation of the small fraction of channels that were not blocked during the conditioning prepulse. The
slow time constant reflects slow dissociation of the drug from the
channels that were blocked during the conditioning prepulse ( drug). For the wild-type channels, drug
was 2.2 ± 0.2 s (Fig. 7A). For I409A,
drug was 1.7 ± 0.1 s, not significantly
different from the drug for the wild-type channels
(p > 0.05) (Fig. 7B). In contrast, N418A
recovered with drug = 0.32 ± 0.03 s
(p < 0.01) (Fig. 7C), 7-fold faster than
the drug for the wild-type channels. Furthermore, in the
presence of 100 µM etidocaine, N418A reached 100%
recovery after ~2 s (Fig. 7C), whereas the control N418A channel had only recovered to ~70% of its initial level by 4 s (Fig. 7A). The dramatically faster recovery of the
drug-bound channel indicates that etidocaine impeded entry into the
slow inactivated state. The faster recovery compared with the WT
channel recovery suggests a lower affinity of the closed inactivated
N418A channel for etidocaine compared with the affinity of the WT
channels. This faster dissociation of etidocaine from N418A contributes to the reduction in frequency-dependent block of this
mutant by etidocaine (Fig. 6). In contrast, the reduction in
frequency-dependent block of I409A must be primarily caused
by the reduced affinity of this mutant for etidocaine because the
mutation has no effect on recovery from etidocaine block.
 |
DISCUSSION |
Role of Amino Acid Residues in the S6 Transmembrane Segments in
Na+ Channel Activation--
Our present results on
mutations in segments IS6 and IIS6 and previously published data on
mutations in segments IIIS6 and IVS6 (20, 30) are summarized in Fig.
8. We used multiple sequence alignment of
all four S6 segments to produce a position-dependent plot
of shifts in the voltage dependence of activation gating (Fig. 8,
Activation Shift) and shifts in the slope factor
(k) of the activation process (Slope Effect).
This plot demonstrates that a number of mutations in the extracellular
part of the S6 segments caused small shifts in the voltage dependence
of activation (Fig. 8, Activation Shift, positions
1-8). Mutations of residues located in the middle part of the S6
segments did not produce significant effects on the voltage dependence
of activation (Fig. 8, Activation Shift, positions
9-12). Mutations in the intracellular part of the S6 segments had
strong effects on the voltage dependence of activation gating (Fig. 8,
Activation Shift, positions 13-21). Therefore, we suggest
that the intracellular part of each of the pore-lining S6 segments
plays an important role in the conformational changes leading to the
opening of the Na+ channel. Mutations of residues at
positions 13 (L975A in segment IIS6 and V1768A in segment IVS6), 14 (N418A in segment IS6 and N1769A in segment IVS6), and 17 (I1469A in
segment IIIS6 and I1772A in segment IVS6) (Fig. 8, Activation
Shift) caused striking positive shifts in the voltage dependence
of activation. The positive shifts in activation gating indicate that
the native residues at these positions make interactions that stabilize
the open state of the channel. Mutations at positions 14 (N418A in
segment IS6, N1466A in segment IIIS6, and N1769A in segment IVS6), 15 (L1467A in segment IIIS6), and 17 (L421C in segment IS6 and I1772A in
segment IVS6) also significantly decreased the steepness of the voltage
dependence of the activation process (Fig. 8, Slope Effect).
All of the native residues at these positions are proposed to face away
from the pore lumen of the Na+ channel (Fig.
9). Therefore, the effects of mutations
of these residues on the slope of the activation process suggest that
these residues may interact with the voltage-sensing S4 segments of the
Na+ channel and alter their transmembrane movement during
activation, resulting in reduced and shifted transmembrane charge
movement.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 8.
Summary of effect of mutations in all four S6
segments on activation and inactivation gating. Left
panel, vertical representation of amino acid sequence alignment of
S6 segments in domains I-IV (see "Experimental Procedures").
Segment IS6 residues are from Phe405 to Ala425.
Segment IIS6 residues are from Phe963 to
Leu983. Segment IIIS6 residues are from Phe1453
to Ile1473. Segment IVS6 residues are from
Phe1756 to Leu1776. Activation
Shift, the half-maximal activation voltage
(V0.5) of S6 segment mutants from domains I-IV
compared with that of the wild-type Na+ channels. The
histogram shows the differences in voltage for the half-maximal
activation of the wild-type and mutant Na+ channels. Mean
V0.5 values were obtained from Boltzmann fits of
normalized conductance versus voltage plots as described in
the legend to Fig. 1. Bars are colored red for
the corresponding mutations in domain I, yellow for
mutations in domain II, green for mutations in domain III,
and blue for mutations in domain IV. The S6 segments were
aligned as described above. Slope Effect, the slope factor
of the activation process (k) of the S6 segment mutants from
domains I-IV compared with that of the wild-type Na+
channels. The histogram shows the differences in k values
for the wild-type and mutant Na+ channels. Mean
k values were obtained from Boltzmann fits of normalized
conductance versus voltage plots as described in the legend
to Fig. 1. Inactivation Shift, the half-maximal inactivation
voltage (V0.5) of S6 segment mutants from
domains I-IV compared with that of the wild-type Na+
channels. The histogram shows the differences in voltage for the
half-maximal inactivation of the wild-type and mutant Na+
channels. Mean V0.5 values were obtained from
Boltzmann fits of normalized current versus voltage plots as
described in the legend to Fig. 2.
|
|

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 9.
Model of etidocaine binding to transmembrane
segments IS6, IIIS6, and IVS6 of the rat brain Nav1.2
channel. A, three-dimensional model (see "Experimental
Procedures") of the proposed orientation of amino acid residues
within the Na+ channel pore with respect to the local
anesthetic etidocaine. Only transmembrane segments IS6
(red), IIIS6 (green), and IVS6 (blue)
are shown. Etidocaine (yellow) is shown in stick
representation. Residues important in etidocaine binding are shown in
space-filling representation. This figure was prepared with
MOLSCRIPT and RASTER-3D (70, 71). B, -helical
representation showing the axial positions of mutations that caused
reduction in the affinity of etidocaine (ETID) for the
inactivated Na+ channels.
|
|
The position-dependent profile of shifts produced by
mutations in the intracellular part of the S6 segments (Fig. 8,
Activation Shift, positions 13-20) is also
consistent with an -helical structure of the S6 segments and with a
rotational motion of this helix during channel activation. Movements of
an intracellular part of the pore-forming S6 segments in the
voltage-dependent K+ channels and the
corresponding M2 segments in KcsA channels have been proposed to
regulate channel opening and closing (59-65). Rotational motion of the
pore-forming M2 segments in the KcsA channels about their helical axis
during activation gating has been detected using EPR (63, 65). By
comparing the structure of KcsA with a newly determined structure of a
Ca2+-activated K+ channel from
Methanobacterium thermoautotrophicum (MthK), Jiang et al. (60) proposed that the M2 segments rotate and
move laterally and outward, resulting in a 12-Å opening at the
intracellular aspect of the pore. This movement hinges on a critical
glycine residue located approximately halfway through the M2 helix,
which is conserved in S6 segments I-III of voltage-gated sodium
channels. Our results suggest that the intracellular part of the S6
segments in Na+ channels also may be involved in rotational
and translational movements during channel opening.
Role of Amino Acid Residues in the S6 Transmembrane Segments in
Na+ Channel Inactivation--
The majority of mutations in
segment IS6 caused positive shifts in the voltage dependence of
inactivation (Fig. 8, Inactivation Shift, red
bars), indicating that the native residues at those positions
favor inactivation from the closed state. In contrast, mutations in
segments IIS6, IIIS6, and IVS6 produced negative shifts in the voltage
dependence of inactivation (Fig. 8, Inactivation Shift,
yellow, green, and blue bars),
indicating that the native residues at those positions oppose
inactivation from the closed state. Large shifts were produced by
alanine mutations in the intracellular half of segment IIIS6 (Fig. 8,
Inactivation Shift, positions 13-21, green
bars), suggesting that the intracellular half of segment IIIS6
plays an important role in a conformational change during the
transition from the closed to the closed inactivated state. Mutations
of several residues in the extracellular half of the S6 segments (Fig.
8, Inactivation Shift, positions 5-7) produced
strong negative shifts in the voltage dependence of inactivation.
Role of Amino Acid Residues at the Intracellular End of Segments
IS6, IIS6, and IVS6 in Na+ Channel Open-state
Inactivation--
Fast inactivation of Na+ channels from
the open state is thought to occur by binding of an intracellular
inactivation gate formed by the loop between domains III and IV to
regions around the channel pore through hydrophobic interactions (8,
66-68). Previous studies have demonstrated that mutation to alanine of three hydrophobic residues at the intracellular end of segment IVS6
strongly disrupts open-state inactivation (19, 20), whereas none of the
alanine mutations in segment IIIS6 disrupt open-state inactivation
(30). Our present results for transmembrane segments IS6 and IIS6
demonstrate that mutations L421C in segment IS6 and L983A in segment
IIS6 disrupted inactivation from the open state and caused
non-inactivating Na+ currents. Thus, amino acid residues at
the intracellular end of segments IS6, IIS6, and IVS6, but not segment
IIIS6, are important for closure of the Na+ channel fast
inactivation gate. These are highly specific interactions because >80
other mutations in the S6 segments did not cause non-inactivating Na+ currents.
Alignment of the four S6 segments of the Na+ channel places
Leu421, Leu983, and Val1774, the
amino acid residues at which alanine substitution greatly impairs
open-state inactivation, at positions 17, 21, and 19 of the S6 helices,
respectively (Fig. 8). Amino acid residues in equivalent positions are
located at the point where the M2 helices cross each other in the
closed three-dimensional structure of the KcsA channel (6) and are just
beyond the most outward amino acids in the S6 segments that are
accessible to methane thiosulfonate reagents applied from the
cytoplasmic surface to the closed conformation of the Shaker K+
channel (64). The equivalent amino acid residues in KcsA are thought to
move laterally to widen the vestibule of the pore as the channel
activates (60, 65, 69). An analogous movement in the sodium channel S6
segments would move the native amino acids near the bundle crossing in
the closed sodium channel laterally and reveal newly accessible side
chain moieties that form part of the receptor for the inactivation gate
and that stabilize the inactivated state. Thus, the specific set of
amino acid residues at which alanine substitution disrupts inactivation
is likely to become accessible upon channel activation and present a
hydrophobic surface to which the IFM motif of the inactivation gate can dock.
Receptor Site for Local Anesthetics and Antiarrhythmic and
Anticonvulsant Drugs within Pore-forming S6 Segments of the
Na+ Channel--
Our previous data for transmembrane
segments IIIS6 (30) and IVS6 (29) and our present results on segments
IS6 and IIS6 give a more complete view of the molecular determinants of
the receptor site for the local anesthetic etidocaine and related pore-blocking drugs. Mutations F1764A and Y1771A in segment IVS6 reduced the affinity of inactivated Na+ channels for
etidocaine by 130- and 35-fold, respectively (29). Mutation I1760A,
also in segment IVS6, did not have a significant effect on etidocaine
affinity, but accelerated the off-rate of etidocaine from the closed
channels at negative potentials (29). Apparently, mutation I1760A
created another pathway for etidocaine to escape from its binding site
(29, 33). Mutations L1465A, N1466A, and I1469A in segment IIIS6 caused
6-, 8-, and 7-fold reductions in the inactivated-state affinity,
respectively (30). Of all the mutations studied in segments IS6 and
IIS6, only mutation I409A in segment IS6 decreased inactivated-state
block by etidocaine by as much as 6-fold. Thus, we propose that
Ile409 in segment IS6 faces the pore lumen in the
inactivated state of the Na+ channel, along with the amino
acid residues in segments IIIS6 and IVS6 that bind local anesthetics
(Fig. 9). None of the segment IIS6 mutations studied had any
significant effect on the inactivated-state affinity of etidocaine or
had an effect on frequency-dependent block by this drug.
Therefore, we cannot define any pore-facing residue(s) in segment IIS6.
Based on the available data for all four S6 segments of the
Na+ channel, we propose a molecular model for the
individual amino acid residues in transmembrane segments IS6, IIIS6,
and IVS6 that form the local anesthetic receptor site (Fig. 9). In
addition to our results, site-directed mutagenesis studies of
Phe1710 and Tyr1717 in segment IVS6 of the rat
brain Nav1.3 channel (homologous to Phe1764 and
Tyr1771, respectively, in the rat brain Nav1.2
channel) introduced mutations varying in size, hydrophobicity, and
aromaticity and demonstrated in more detail how these
residues influence local anesthetic drug binding (38). Block of open
and inactivated channels by the local anesthetic tetracaine required an
aromatic residue at position 1710 of the Nav1.3 channel.
This phenylalanine residue is positioned in the middle of segment IVS6
(Fig. 9) and could stabilize the drug binding to the open or
inactivated states by either cation- or aromatic-aromatic
interactions between the aromatic side chain of the amino acid and
charged or aromatic moieties on the drug molecule (38). Therefore,
Nav1.3 channel Phe1710 (homologous to
Nav1.2 channel Phe1764) has been proposed to
contribute directly to the local anesthetic receptor site (38). In
contrast, effects on drug action of mutations of Nav1.3
channel Tyr1717 (homologous to Nav1.2 channel
Tyr1771) were not well correlated with the size,
hydrophobicity, or aromaticity of the substituted amino acid. Further
studies are necessary to determine whether Ile409 in
segment IS6 and Leu1465, Asn1466, and
Ile1469 in segment IIIS6 contribute directly to the local
anesthetic receptor site, but this is the most straightforward
conclusion from the experimental results presented here.
None of the segment IS6 or IIS6 mutations studied had any significant
effect on inactivated-state affinity or frequency-dependent block by sipatrigine, suggesting that its binding contacts are all in
segments IIIS6 and IVS6. Similarly, the mutations in segment IS6 that
had effects on etidocaine binding and block had no effect on block by
the anticonvulsant lamotrigine. Therefore, our results to date suggest
that amino acid residues in segments IIIS6 and IVS6 form the receptor
site for these anticonvulsant drugs, with little participation of amino
acid residues in segment IS6 or IIS6. These different molecular
interactions may underlie the different kinetic effects and therapeutic
uses of the anticonvulsant and local anesthetic Na+
channel-blocking drugs.
The lateral movement of M2 segments and the resulting large
intracellular opening proposed to occur as KcsA/MthK open channels (6,
60) have important implications for drug block of voltage-gated sodium
channels. First, the intracellular opening is critical for allowing
rapid access of large blocking compounds to their binding sites within
the pore. Second, the glycine responsible for S6 segment flexibility in
channel opening is absent in segment IVS6, the segment where alanine
substitutions cause the most marked state-dependent
disruptions in drug block. The lack of a glycine suggests that segment
IVS6 may be less mobile and therefore may maintain an angled
disposition relative to the pore axis or undergo a smaller
conformational change during activation. The different gating movement
of segment IVS6 may contribute to its primary role in drug binding.
State-dependent drug block may result from the small
movement of segment IVS6 or from larger movements of other S6 segments,
perhaps relieving steric hindrance near critical binding residues such
as Phe1764 and Tyr1771 in segment IVS6.
 |
FOOTNOTES |
*
This work was supported by Research Grant R-01 N515751 from
the National Institutes of Health (to W. A. C.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology,
P. O. Box 357280, Seattle, WA 98195-7280. Tel.: 206-543-1925; Fax:
206-543-3882; E-mail: wcatt@u.washington.edu.
Published, JBC Papers in Press, July 18, 2002, DOI 10.1074/jbc.M206126200
 |
ABBREVIATIONS |
The abbreviation used is:
WT, wild-type.
 |
REFERENCES |
| 1.
|
Hille, B.
(2001)
Ionic Channels of Excitable Membranes
, 3rd Ed.
, Sinauer Associates, Inc., Sunderland, MA
|
| 2.
|
Catterall, W. A.
(2000)
Neuron
26,
13-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Cohen, S. A.,
and Barchi, R. L.
(1993)
Int. Rev. Cytol.
137C,
55-103[Medline]
[Order article via Infotrieve]
|
| 4.
|
Fozzard, H. A.,
and Hanck, D. A.
(1996)
Physiol. Rev.
76,
887-926[Abstract/Free Full Text]
|
| 5.
|
Marban, E.,
Yamagishi, T.,
and Tomaselli, G.
(1998)
J. Physiol. (Lond.)
508,
647-657[Abstract/Free Full Text]
|
| 6.
|
Doyle, D. A.,
Cabral, J. M.,
Pfuetzner, R. A.,
Kuo, A. L.,
Gulbis, J. M.,
Cohen, S. L.,
Chait, B. T.,
and MacKinnon, R.
(1998)
Science
280,
69-77[Abstract/Free Full Text]
|
| 7.
|
Hodgkin, A. L.,
and Huxley, A. F.
(1952)
J. Physiol. (Lond.)
117,
500-544
|
| 8.
|
Armstrong, C. M.
(1981)
Physiol. Rev.
61,
644-683[Free Full Text]
|
| 9.
|
Catterall, W. A.
(1986)
Trends Neurosci.
9,
7-10
|
| 10.
|
Guy, H. R.,
and Seetharamulu, P.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
508-512[Abstract/Free Full Text]
|
| 11.
|
Stühmer, W.,
Conti, F.,
Suzuki, H.,
Wang, X. D.,
Noda, M.,
Yahagi, N.,
Kubo, H.,
and Numa, S.
(1989)
Nature
339,
597-603[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Kontis, K. J.,
Rounaghi, A.,
and Goldin, A. L.
(1997)
J. Gen. Physiol.
110,
391-401[Abstract/Free Full Text]
|
| 13.
|
Yang, N.,
and Horn, R.
(1995)
Neuron
15,
213-218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Cha, A.,
Ruben, P. C.,
George, A. L., Jr.,
Fujimoto, E.,
and Bezanilla, F.
(1999)
Neuron
22,
73-87[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Yang, N.,
George, A. L., Jr.,
and Horn, R.
(1996)
Neuron
16,
113-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Vassilev, P. M.,
Scheuer, T.,
and Catterall, W. A.
(1988)
Science
241,
1658-1661[Abstract/Free Full Text]
|
| 17.
|
Vassilev, P.,
Scheuer, T.,
and Catterall, W. A.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
8147-8151[Abstract/Free Full Text]
|
| 18.
|
West, J. W.,
Patton, D. E.,
Scheuer, T.,
Wang, Y.,
Goldin, A. L.,
and Catterall, W. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10910-10914[Abstract/Free Full Text]
|
| 19.
|
McPhee, J. C.,
Ragsdale, D. S.,
Scheuer, T.,
and Catterall, W. A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12346-12350[Abstract/Free Full Text]
|
| 20.
|
McPhee, J. C.,
Ragsdale, D. S.,
Scheuer, T.,
and Catterall, W. A.
(1995)
J. Biol. Chem.
270,
12025-12034[Abstract/Free Full Text]
|
| 21.
|
Smith, M. R.,
and Goldin, A. L.
(1997)
Biophys. J.
73,
1885-1895[Medline]
[Order article via Infotrieve]
|
| 22.
|
Lerche, H.,
Peter, W.,
Fleischhauer, R.,
PikaHartlaub, U.,
Malina, T.,
Mitrovic, N.,
and Lehmann-Horn, F.
(1997)
J. Physiol. (Lond.)
505,
345-352[Abstract/Free Full Text]
|
| 23.
|
Filatov, G. N.,
Nguyen, T. P.,
Kraner, S. D.,
and Barchi, R. L.
(1998)
J. Gen. Physiol.
111,
703-715[Abstract/Free Full Text]
|
| 24.
|
McPhee, J. C.,
Ragsdale, D. S.,
Scheuer, T.,
and Catterall, W. A.
(1998)
J. Biol. Chem.
273,
1121-1129[Abstract/Free Full Text]
|
| 25.
|
Tang, L.,
Chehab, N.,
Wieland, S. J.,
and Kallen, R. G.
(1998)
J. Gen. Physiol.
111,
639-652[Abstract/Free Full Text]
|
| 26.
|
Chen, L. Q.,
Santarelli, V.,
Horn, R.,
and Kallen, R. G.
(1996)
J. Gen. Physiol.
108,
549-556[Abstract/Free Full Text]
|
| 27.
|
Rogers, J. C., Qu, Y.,
Tanada, T. N.,
Scheuer, T.,
and Catterall, W. A.
(1996)
J. Biol. Chem.
271,
15950-15962[Abstract/Free Full Text]
|
| 28.
|
Sheets, M. F.,
Kyle, J. W.,
Kallen, R. G.,
and Hanck, D. A.
(1999)
Biophys. J.
77,
747-757[Medline]
[Order article via Infotrieve]
|
| 29.
|
Ragsdale, D. S.,
McPhee, J. C.,
Scheuer, T.,
and Catterall, W. A.
(1994)
Science
265,
1724-1728[Abstract/Free Full Text]
|
| 30.
|
Yarov-Yarovoy, V.,
Brown, J.,
Sharp, E. M.,
Clare, J. J.,
Scheuer, T.,
and Catterall, W. A.
(2001)
J. Biol. Chem.
276,
20-27[Abstract/Free Full Text]
|
| 31.
|
Liu, G.,
Scheuer, T.,
and Catterall, W. A.
(1998)
Biophys. J.
74,
A399 (abstr.)
|
| 32.
|
Goldin, A. L.,
Barchi, R. L.,
Caldwell, J. H.,
Hofmann, F.,
Howe, J. R.,
Hunter, J. C.,
Kallen, R. G.,
Mandel, G.,
Meisler, M. H.,
Netter, Y. B.,
Noda, M.,
Tamkun, M. M.,
Waxman, S. G.,
Wood, J. N.,
and Catterall, W. A.
(2000)
Neuron
28,
365-368[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Qu, Y.,
Rogers, J.,
Tanada, T.,
Scheuer, T.,
and Catterall, W. A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11839-11843[Abstract/Free Full Text]
|
| 34.
|
Ragsdale, D. S.,
McPhee, J. C.,
Scheuer, T.,
and Catterall, W. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9270-9275[Abstract/Free Full Text]
|
| 35.
|
Wang, G. K.,
Quan, C.,
and Wang, S.
(1998)
Pfluegers Arch. Eur. J. Physiol.
435,
293-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Wright, S. N.,
Wang, S. Y.,
and Wang, G. K.
(1998)
Mol. Pharmacol.
54,
733-739[Abstract/Free Full Text]
|
| 37.
|
Weiser, T., Qu, Y.,
Catterall, W. A.,
and Scheuer, T.
(1999)
Mol. Pharmacol.
56,
1238-1244[Abstract/Free Full Text]
|
| 38.
|
Li, H. L.,
Galue, A.,
Meadows, L.,
and Ragsdale, D. S.
(1999)
Mol. Pharmacol.
55,
134-141[Abstract/Free Full Text]
|
| 39.
|
Carter, A. J.,
Grauert, M.,
Pschorn, U.,
Bechtel, W. D.,
Bartmann-Lindholm, C., Qu, Y.,
Scheuer, T.,
Catterall, W. A.,
and Weiser, T.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
4944-4949[Abstract/Free Full Text]
|
| 40.
|
Wang, S. Y.,
Nau, C.,
and Wang, G. K.
(2000)
Biophys. J.
79,
1379-1387[Medline]
[Order article via Infotrieve]
|
| 41.
|
Wang, G. K.,
Quan, C.,
and Wang, S. Y.
(1998)
Mol. Pharmacol.
54,
389-396[Abstract/Free Full Text]
|
| 42.
|
Jeanmougin, F.,
Thompson, J. D.,
Gouy, M.,
Higgins, D. G.,
and Gibson, T. J.
(1998)
Trends Biochem. Sci.
23,
403-405[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Penzotti, J. L.,
Fozzard, H. A.,
Lipkind, G. M.,
and Dudley, S. C., Jr.
(1998)
Biophys. J.
75,
2647-2657[Medline]
[Order article via Infotrieve]
|
| 44.
|
Li, R. A.,
Ennis, I. L.,
French, R. J.,
Dudley, S. C., Jr.,
Tomaselli, G. F.,
and Marban, E.
(2001)
J. Biol. Chem.
276,
11072-11077[Abstract/Free Full Text]
|
| 45.
|
Richardson, J. S.
(1981)
Adv. Protein Chem.
34,
167-339[Medline]
[Order article via Infotrieve]
|
| 46.
|
Blaber, M.,
Zhang, X. J.,
and Matthews, B. W.
(1993)
Science
260,
1637-1640[Abstract/Free Full Text]
|
| 47.
|
Hille, B.
(1977)
J. Gen. Physiol.
69,
497-515[Abstract/Free Full Text]
|
| 48.
|
Hondeghem, L. M.,
and Katzung, B. G.
(1977)
Biochim. Biophys. Acta
472,
373-398[Medline]
[Order article via Infotrieve]
|
| 49.
|
Catterall, W. A.
(1987)
Trends Pharmacol. Sci.
8,
57-65[CrossRef]
|
| 50.
|
Xie, X. M.,
and Garthwaite, J.
(1996)
Neuroscience
73,
951-962[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Calabresi, P.,
Stefani, A.,
Marfia, G. A.,
Hainsworth, A. H.,
Centonze, D.,
Saulle, E.,
Spadoni, F.,
Leach, M. J.,
Giacomini, P.,
and Bernardi, G.
(2000)
Exp. Neurol.
162,
171-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Leach, M. J.,
Swan, J. H.,
Eisenthal, D.,
Dopson, M.,
and Nobbs, M.
(1993)
Stroke
24,
1063-1067[Abstract/Free Full Text]
|
| 53.
|
Muir, K. W.,
Holzapfel, L.,
and Lees, K. R.
(2000)
Cerebrovasc. Dis.
10,
431-436[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Muir, K. W.,
Hamilton, S. J.,
Lunnon, M. W.,
Hobbiger, S.,
and Lees, K. R.
(1998)
Cerebrovasc. Dis.
8,
31-37[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Muir, K. W.,
Lees, K. R.,
Hamilton, S. J.,
George, C. F.,
Hobbiger, S. F.,
and Lunnon, M. W.
(1995)
Ann. N. Y. Acad. Sci.
765,
328-329[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Kuo, C. C.,
and Bean, B. P.
(1994)
Mol. Pharmacol.
46,
716-725[Abstract]
|
| 57.
|
Butterworth, J. F.,
and Strichartz, G. R.
(1990)
Anesthesiology
72,
711-734[Medline]
[Order article via Infotrieve]
|
| 58.
|
Wang, S. Y.,
and Wang, G. K.
(1997)
Biophys. J.
72,
1633-1640[Medline]
[Order article via Infotrieve]
|
| 59.
|
Liu, Y.,
Holmgren, M.,
Jurman, M. E.,
and Yellen, G.
(1997)
Neuron
19,
175-184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Jiang, Y.,
Lee, A.,
Chen, J.,
Cadene, M.,
Chait, B. T.,
and MacKinnon, R.
(2002)
Nature
417,
523-526[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Perozo, E.,
Cortes, D. M.,
and Cuello, L. G.
(1998)
Nat. Struct. Biol.
5,
459-469[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Holmgren, M.,
Shin, S. H.,
and Yellen, G.
(1998)
Neuron
21,
617-621[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Perozo, E.,
Cortes, D. M.,
and Cuello, L. G.
(1999)
Science
285,
73-78[Abstract/Free Full Text]
|
| 64.
|
del Camino, D.,
Holmgren, M.,
Liu, Y.,
and Yellen, G.
(2000)
Nature
403,
321-325[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Liu, Y. S.,
Sompornpisut, P.,
and Perozo, E.
(2001)
Nat. Struct. Biol.
8,
883-887[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Armstrong, C. M.,
and Bezanilla, F.
(1977)
J. Gen. Physiol.
70,
567-590[Abstract/Free Full Text]
|
| 67.
|
Zagotta, W. N.,
and Aldrich, R. W.
(1990)
J. Gen. Physiol.
95,
29-60[Abstract/Free Full Text]
|
| 68.
|
Hoshi, T.,
Zagotta, W. N.,
and Aldrich, R. W.
(1991)
Neuron
7,
547-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Kong, Y.,
Shen, Y.,
Warth, T. E.,
and Ma, J.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
5999-6004[Abstract/Free Full Text]
|
| 70.
|
Kraulis, P. J.
(1991)
J. Appl. Crystallogr.
24,
946-950[CrossRef]
|
| 71.
|
Merritt, E. A.,
and Bacon, D. J.
(1997)
Methods Enzymol.
277,
505-524[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. E. Browne, F. E. Blaney, S. P. Yusaf, J. J. Clare, and D. Wray
Structural Determinants of Drugs Acting on the Nav1.8 Channel
J. Biol. Chem.,
April 17, 2009;
284(16):
10523 - 10536.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Muroi and B. Chanda
Local Anesthetics Disrupt Energetic Coupling between the Voltage-sensing Segments of a Sodium Channel
J. Gen. Physiol.,
December 29, 2008;
133(1):
1 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Bruhova, D. B. Tikhonov, and B. S. Zhorov
Access and Binding of Local Anesthetics in the Closed Sodium Channel
Mol. Pharmacol.,
October 1, 2008;
74(4):
1033 - 1045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Barajas-Martinez, D. Hu, J. M. Cordeiro, Y. Wu, R. J. Kovacs, H. Meltser, H. Kui, B. Elena, R. Brugada, C. Antzelevitch, et al.
Lidocaine-Induced Brugada Syndrome Phenotype Linked to a Novel Double Mutation in the Cardiac Sodium Channel
Circ. Res.,
August 15, 2008;
103(4):
396 - 404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Ahern, A. L. Eastwood, D. A. Dougherty, and R. Horn
Electrostatic Contributions of Aromatic Residues in the Local Anesthetic Receptor of Voltage-Gated Sodium Channels
Circ. Res.,
January 4, 2008;
102(1):
86 - 94.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Chancey, P. E. Shockett, and J. P. O'Reilly
Relative resistance to slow inactivation of human cardiac Na+ channel hNav1.5 is reversed by lysine or glutamine substitution at V930 in D2-S6
Am J Physiol Cell Physiol,
December 1, 2007;
293(6):
C1895 - C1905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Susankova, R. Ettrich, L. Vyklicky, J. Teisinger, and V. Vlachova
Contribution of the Putative Inner-Pore Region to the Gating of the Transient Receptor Potential Vanilloid Subtype 1 Channel (TRPV1)
J. Neurosci.,
July 11, 2007;
27(28):
7578 - 7585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Sheets and D. A. Hanck
Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels
J. Physiol.,
July 1, 2007;
582(1):
317 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. McNulty, G. B. Edgerton, R. D. Shah, D. A. Hanck, H. A. Fozzard, and G. M. Lipkind
Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels
J. Physiol.,
June 1, 2007;
581(2):
741 - 755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Jones, Y. Wang, M. D. Smith, N. J. Hargus, H. S. Eidam, H. S. White, J. Kapur, M. L. Brown, and M. K. Patel
Hydroxyamide Analogs of Propofol Exhibit State-Dependent Block of Sodium Channels in Hippocampal Neurons: Implications for Anticonvulsant Activity
J. Pharmacol. Exp. Ther.,
February 1, 2007;
320(2):
828 - 836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Raybaud, Y. Dodier, P. Bissonnette, M. Simoes, D. G. Bichet, R. Sauve, and L. Parent
The Role of the GX9GX3G Motif in the Gating of High Voltage-activated Ca2+ Channels
J. Biol. Chem.,
December 22, 2006;
281(51):
39424 - 39436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. McNulty, J. W. Kyle, G. M. Lipkind, and D. A. Hanck
An Inner Pore Residue (Asn406) in the Nav1.5 Channel Controls Slow Inactivation and Enhances Mibefradil Block to T-Type Ca2+ Channel Levels
Mol. Pharmacol.,
November 1, 2006;
70(5):
1514 - 1523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. M. Smith, S. M. Amagasu, J. Hembrador, S. Axt, R. Chang, T. Church, C. Gee, J. R. Jacobsen, T. Jenkins, E. Kaufman, et al.
Evidence for a Multivalent Interaction of Symmetrical, N-Linked, Lidocaine Dimers with Voltage-Gated Na+ Channels
Mol. Pharmacol.,
March 1, 2006;
69(3):
921 - 931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Lipkind and H. A. Fozzard
Molecular Modeling of Local Anesthetic Drug Binding by Voltage-Gated Sodium Channels
Mol. Pharmacol.,
December 1, 2005;
68(6):
1611 - 1622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Ulbricht
Sodium Channel Inactivation: Molecular Determinants and Modulation
Physiol Rev,
October 1, 2005;
85(4):
1271 - 1301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ding, L. Ingleby, C. A. Ahern, and R. Horn
Investigating the Putative Glycine Hinge in Shaker Potassium Channel
J. Gen. Physiol.,
August 29, 2005;
126(3):
213 - 226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Y. Tsang, R. G. Tsushima, G. F. Tomaselli, R. A. Li, and P. H. Backx
A Multifunctional Aromatic Residue in the External Pore Vestibule of Na+ Channels Contributes to the Local Anesthetic Receptor
Mol. Pharmacol.,
February 1, 2005;
67(2):
424 - 434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhao, T. Scheuer, and W. A. Catterall
Reversed voltage-dependent gating of a bacterial sodium channel with proline substitutions in the S6 transmembrane segment
PNAS,
December 21, 2004;
101(51):
17873 - 17878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sunami, A. Tracey, I. W Glaaser, G. M Lipkind, D. A Hanck, and H. A Fozzard
Accessibility of mid-segment domain IV S6 residues of the voltage-gated Na+ channel to methanethiosulfonate reagents
J. Physiol.,
December 1, 2004;
561(2):
403 - 413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-Y. Wang, J. Mitchell, E. Moczydlowski, and G. K. Wang
Block of Inactivation-deficient Na+ Channels by Local Anesthetics in Stably Transfected Mammalian Cells: Evidence for Drug Binding Along the Activation Pathway
J. Gen. Physiol.,
November 29, 2004;
124(6):
691 - 701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Sandtner, J. Szendroedi, T. Zarrabi, E. Zebedin, K. Hilber, I. Glaaser, H. A. Fozzard, S. C. Dudley, and H. Todt
Lidocaine: A Foot in the Door of the Inner Vestibule Prevents Ultra-Slow Inactivation of a Voltage-Gated Sodium Channel
Mol. Pharmacol.,
September 1, 2004;
66(3):
648 - 657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Li, K. Migita, D. S. K. Samways, M. M. Voigt, and T. M. Egan
Gain and Loss of Channel Function by Alanine Substitutions in the Transmembrane Segments of the Rat ATP-Gated P2X2 Receptor
J. Neurosci.,
August 18, 2004;
24(33):
7378 - 7386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. De Luca, S. Talon, M. De Bellis, J.-F. Desaphy, G. Lentini, F. Corbo, A. Scilimati, C. Franchini, V. Tortorella, and D. C. Camerino
Optimal Requirements for High Affinity and Use-Dependent Block of Skeletal Muscle Sodium Channel by N-Benzyl Analogs of Tocainide-Like Compounds
Mol. Pharmacol.,
October 1, 2003;
64(4):
932 - 945.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kondratiev and G. F. Tomaselli
Altered Gating and Local Anesthetic Block Mediated by Residues in the I-S6 and II-S6 Transmembrane Segments of Voltage-Dependent Na+ Channels
Mol. Pharmacol.,
September 1, 2003;
64(3):
741 - 752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. K. Wang, C. Russell, and S.-Y. Wang
State-dependent Block of Wild-type and Inactivation-deficient Na+ Channels by Flecainide
J. Gen. Physiol.,
August 25, 2003;
122(3):
365 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Ouyang, G. Wang, and H. C. Hemmings Jr
Isoflurane and Propofol Inhibit Voltage-Gated Sodium Channels in Isolated Rat Neurohypophysial Nerve Terminals
Mol. Pharmacol.,
August 1, 2003;
64(2):
373 - 381.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Nau, S.-Y. Wang, and G. K. Wang
Point Mutations at L1280 in Nav1.4 Channel D3-S6 Modulate Binding Affinity and Stereoselectivity of Bupivacaine Enantiomers
Mol. Pharmacol.,
June 1, 2003;
63(6):
1398 - 1406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. K. Wang and S.-Y. Wang
Veratridine block of rat skeletal muscle Nav1.4 sodium channels in the inner vestibule
J. Physiol.,
May 1, 2003;
548(3):
667 - 675.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Liu, J. Atkins, and R. S. Kass
Common Molecular Determinants of Flecainide and Lidocaine Block of Heart Na+ Channels: Evidence from Experiments with Neutral and Quaternary Flecainide Analogues
J. Gen. Physiol.,
February 24, 2003;
121(3):
199 - 214.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|